• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

John Legend Is High on a CBD Startup Called Plus Products

Singer teamed up with company this week, sending its stock on a wild ride.
By DEBRA BORCHARDT
Sep 19, 2019 | 09:18 AM EDT
Stocks quotes in this article: PLPRF

It wasn't long ago that Jake Heimark, the 31-year old CEO of cannabis-edible company Plus Products (PLPRF) was fighting to save his company. Known for its cannabis-infused gummies, Plus was mostly limited to California -- and while consumers liked the product, the company was struggling. But this week, Plus shares popped when the company teamed up with superstar musician John Legend and mattress giant Casper Sleep Inc. to launch a line of CBD-infused gummies aimed at helping people with sleep problems and other ailments.

The news sent PLPRF shares 11% higher to close at $3.95 on Tuesday, although they gave back much of those gains to close at $3.64 (-7.9%) on Wednesday.

The high-profile deal represents a big win for Plus and Heimark, who not that long ago was just trying to keep the company afloat. "Three years ago, I couldn't make payroll. My top executives were taking pay cuts," the CEO candidly admitted during a symposium at this month's Green Market Summit in Los Angeles.

Heimark added that when asked why he took the company public before Plus seemed ready, he answers: "I had taken my parents' money, my friends' parents' money, my friends' money. I couldn't lose that."

In fact, the CEO not only took seed money from friends and relatives, but also runs Plus with his family's help. Heimark's dad is chairman of the board and chief strategic officer and also served as chief financial officer until May. Even Heimark's mother works with the company.

It was this commitment to family that helped draw Legend to the company. The singer was already a firm believer in CBD's benefits, but he's also an avowed family man himself. Legend and his famous wife, model Chrissy Teigen, fill their social-media accounts with images of family activities.

"We love the values of this company," Legend said this week at the new product's launch. "We love that they're committed to research, science and doing the work to back up the anecdotal claims that a lot of people think they know about CBD. They want to make sure people are taking the right doses. So, we really respect the values of this company."

John Legend (right) is partnering with CEO Jake Heimark (center) of Plus Products to sell CBD-infused gummies.
John Legend (right) is partnering with CEO Jake Heimark (center) of Plus Products to sell CBD-infused gummies.

Legend, Casper and Plus are teaming up to launch a nationwide line of hemp-derived CBD gummies that focus on three health reasons why consumers are drawn to CBD products in the first place. There are new Plus Balance gummies, Plus Uplift gummies and Plus Sleep gummies.

Consumers often buy marijuana for help with things like sleep problems. For example, one study found that consuming cannabis reduced REM sleep, which resulted in deeper sleep while cutting down on dreams (or nightmares, for those with post-traumatic stress disorder).

Plus gummies omit marijuana's psychoactive THC, but add in melatonin. The company believes that can give people with a lift, which sounds good to Legend.

"My very first album was called 'Get Lifted,' but I've never had a CBD partnership before. I've finally found a company that I really wanted to work with and grow with," Legend said at this week's launch party." Let's keep getting lifted."

The deal certainly lifted PLPRF's stock price on Tuesday, if only briefly. Canaccord Genuity analyst Bobby Burleson rates the company as a "speculative buy," with a C$8 price target ($6 in U.S. dollars at current exchange rates).

Burleson's estimates didn't include any sales beyond California, nor did they consider the company's new product line. But still, he wrote in a March note that "we believe successful expansion could drive as much as 100% upside to our estimates for revenue, and greater upside for EBITDA."

Overcoming Early Struggles

Plus currently has the No. 1 and No. 2 best-selling products in California, according to BDS Analytics. That makes it hard to believe the company ever struggled.

But Heimark readily admits the company made mistakes in the early days. For instance, Plus initially launched with a cannabis-infused chewing gum that didn't sell well.

Chewing gum continues to be a slow category for the industry, but gummies have proven quite popular. The company has also launched a line of mints, and late last year acquired a baked-goods company called GOOD.

But to make such a switch and grow the company, PLPRF needed more money. Fortunately, with all of the capital flooding the cannabis industry these days, it's difficult to imagine no one wanting to invest in Plus. Key investors came from Canada, but their caveat was that the company had to go public quickly so that backers could recoup their investment.

Over the longer term, Plus reported has reported sales of $3.5 million for 2019's second quarter. That's a nice jump over $1.5 million during the same period last year.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Borchardt had no positions in any securities mentioned.

Please note that due to factors including low market capitalization and/or insufficient public float, we consider several names mentioned to be small-cap stocks. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

TAGS: Fundamental Analysis | Investing | Stocks | U.S. Equity | Cannabis

More from Stocks

Will Markets See Positive Fireworks Into the July 4th Weekend?

James "Rev Shark" DePorre
Jun 29, 2022 11:01 AM EDT

In the last 10 years, the three days in front of the July 4th holiday have been up nine times.

Carnival Traders Are Voting With Their Feet

Bruce Kamich
Jun 29, 2022 10:38 AM EDT

Let's review the charts and indicators.

Bed Bath & Beyond Goes From Bad to Really Bad: Here's How to Trade It

Stephen Guilfoyle
Jun 29, 2022 10:30 AM EDT

BBBY just released the firm's first quarter financial results. It reads like fiction.

Bearish Sentiment Is at Decade Highs -- And That's Very Bullish

Guy Ortmann
Jun 29, 2022 10:25 AM EDT

Support levels have held and need to stay in that condition.

Losses Keep Piling Up in 2022 for This Portfolio of 2021 Losers

Jonathan Heller
Jun 29, 2022 10:00 AM EDT

In past years the Tax Loss Selling Recovery Portfolio has performed pretty darn well versus the broad indexes; that isn't the case this year.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:56 AM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    Check out what's going on in the Stocks Under $10 ...
  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login